Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Pamela Munster
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Pamela Munster
Professor, Medicine. Authored (or co-authored) 129 research publications.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT02900651
- Phase
- Phase 1/2
- Study Type
- Interventional
- Last Updated